505 - Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort

Saturday, October 19, 2024

10:45 AM – 11:00 AM US PT

Location: 411

Presenting Author(s)

Moti Ramgopal, MD, FACP, FIDSA (he/him/his)

Medical Director
Midway Immunology and Research Center
Fort Pierce, FL, United States

Slides

Co-Author(s)

CB

Carolyn A. Brown, MSPH, PhD

ViiV Healthcare
Atlanta, Georgia, United States
AF

Andrew Frick, MS

Trio Health
La Mirada, California, United States
JR

Janna Radtchenko, MBA

Senior Director, Analytics
Trio Health
Louisville, Colorado, United States
GS

Gayathri Sridhar, MBBS, MPH, PhD

Director
ViiV Healthcare
Fairfax, Virginia, United States
LR

Leigh Ragone, MS

Strategy & Governance Director
ViiV Healthcare
RTP, North Carolina, United States
Jv

Jean A. van Wyk, MBChB, MFPM

Medical Director
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom
KM

Karam Mounzer, MD (he/him/his)

Clinical Professor of Medicine The Perelman School of Medicine at the University of Pennsylvania
Philadelphia Fight Community Health Centers
Philadelphia, Pennsylvania, United States
PB

Paul Benson, DO

HIV Specialist
Be Well Medical Center
Berkley, MI, United States
SS

Steven Santiago, MD

Chief Medical Officer
CareResource
Miami, Florida, United States
SR

Sebastian Ruhs, MD

Chase Brexton Health Care
Baltimor, Maryland, United States
GH

Gregory Huhn, MD, MPHTM

Attending Physician
The Ruth M. Rothstein CORE CENTER
Chicago, Illinois, United States
KM

Kenneth H. Mayer, MD, MPH

Professor of Medicine
Harvard Medical School/Fenway Research Institute
Boston, MA, United States
Rick A. Elion, MD (he/him/his)

Clinical Professor of Medicine George Washington University School of Medicine
Trio Health
Louisville, Colorado, United States
Vani Vannappagari, MBBS, MPH, PhD

Global Head, Epidemiology & Real World Evidence
ViiV Healthcare
Research Triangle Park, North Carolina, United States

Disclosure(s):

Moti Ramgopal, MD, FACP, FIDSA: Gilead Sciences: Advisor/Consultant, Grant/Research Support, Honoraria; Janssen: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support; ViiV Healthcare: Advisor/Consultant, Grant/Research Support, Honoraria

Carolyn A. Brown, MSPH, PhD: ViiV Healthcare/GSK: Stocks/Bonds (Public Company)

Andrew Frick, MS: Trio Health: Employee

Janna Radtchenko, MBA: Trio Health: Employee

Gayathri Sridhar, MBBS, MPH, PhD: GlaxoSmithKline: Stocks/Bonds (Public Company); ViiV Healthcare: Full Time Employee

Leigh Ragone, MS: GlaxoSmithKline: Stocks/Bonds (Public Company); ViiV Healthcare: Full time employee

Jean A. van Wyk, MBChB, MFPM: ViiV Healthcare: Employee, Stocks/Bonds (Public Company)

Karam Mounzer, MD: Epividian: Board Member, Honoraria; GS: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant; THERA Technologies: Grant/Research Support; ViiV healthcare: Advisor/Consultant, Grant/Research Support, Honoraria

Paul Benson, DO: ViiV Healthcare: Advisor/Consultant, Grant/Research Support, Honoraria

Steven Santiago, MD: Gilead Sciences: Advisor/Consultant, Honoraria; Janssen: Honoraria

Sebastian Ruhs, MD: No financial relationships to disclose

Gregory Huhn, MD, MPHTM: Eli Lilly: Grant/Research Support; Gilead Sciences: Advisor/Consultant, Grant/Research Support, Honoraria; Janssen: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Honoraria; ViiV Healthcare: Grant/Research Support

Kenneth H. Mayer, MD, MPH: Gilead Sciences: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; ViiV Healthcare: Grant/Research Support

Rick A. Elion, MD: Gilead Sciences: Advisor/Consultant, Grant/Research Support, Honoraria; Janssen: Honoraria; Proteus: Grant/Research Support; Trio Health: Employee; ViiV Healthcare: Advisor/Consultant

Vani Vannappagari, MBBS, MPH, PhD: GSK: Stocks/Bonds (Public Company); ViiV Healthcare: Full time Employee, Stocks/Bonds (Public Company)